Neoprobe Licenses RIGS-Related Patents

Neoprobe, a diversified developer of innovative oncology diagnostic and treatment products and cardiovascular surgical and diagnostic products, announced that it has completed a license agreement for U.S. Patent Nos. 6,418,338 and 6,760,612 B2 issued July 9, 2002 and July 6, 2004, respectively. The patents provide Neoprobe with an extension of methodology patent protection that complements the patents covering the targeting agents used in the RIGS technology and extend the potential methodology patent protection for the RIGS technology through 2018.

MENAFN (http://menafn.com/qn_news_story.asp?StoryId=CqLinqbKbmdK1yJG1mJK)